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Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) with donor lymphocyte
infusion is the mainstay of treatment for many types of hematological malignancies, but
the therapeutic effect and prevention of relapse is complicated by donor T-cell recognition
and attack of host tissue in a process known as graft-versus-host disease (GvHD). Cyto-
toxic myeloablative conditioning regimens used prior to Allo-HSCT result in the release
of endogenous innate immune activators that are increasingly recognized for their role
in creating a pro-inflammatory milieu. This increased inflammatory state promotes allo-
geneic T-cell activation and the induction and perpetuation of GvHD. Here, we review the
processes of cellular response to injury and cell death that are relevant following Allo-HSCT
and present the current evidence for a causative role of a variety of endogenous innate
immune activators in the mediation of sterile inflammation following Allo-HSCT. Finally, we
discuss the potential therapeutic strategies that target the endogenous pathways of innate
immune activation to decrease the incidence and severity of GvHD following Allo-HSCT.
Keywords: endogenous innate immune, graft-versus-host disease, hematopoietic stem cell transplantation,
tissue injury
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT)
with donor lymphocyte infusion is currently the treatment of
choice for several types of hematological malignancies associated
with high rates of relapse, including chronic myeloid leukemia
(CML) in adults and acute myeloid leukemia (AML) and acute
lymphoid leukemia (ALL) in children and adults (1). While donor
lymphocytes are critical for the prevention of tumor relapse, they
also cause graft-versus-host disease (GvHD), the major compli-
cation of Allo-HSCT (2). Clinical manifestations of acute GvHD
include rash, diarrhea, gastrointestinal hemorrhage, and jaundice,
which result from immune-mediated injury to the epithelial cells
of the skin, gastrointestinal tract, and liver, respectively. In severe
cases, GvHD can be fatal and is the leading cause of mortality of
Allo-HSCT recipients.
Allogeneic hematopoietic stem cell transplantation requires
myeloablation by total body irradiation (TBI) and/or chemother-
apy in order to provide space in the hematopoietic compartment
for the engraftment of donor hematopoietic stem cells. TBI and
chemotherapy also provide lymphocyte suppression necessary to
prevent immunological rejection of the Allo-HSCT graft, which
can be mediated by even small amounts of host immune defense.
These myeloablative “conditioning” regimens result in cellular
damage and death that produce sterile inflammatory immune
responses through the release of endogenous innate immune-
stimulatory molecules referred to as damage-associated molecular
patterns, or “DAMPs” (3–5) (Figure 1). Endogenous molecules
such as uric acid (5), adenosine triphosphate (ATP) (6), deoxyri-
bonucleic acid (DNA) (7), N -formyl peptides (NFPs) (8), and
heparan sulfate (9) activate specific pattern recognition recep-
tors (PRRs) on innate immune cells. An increasing number of
PRRs have been identified; of these some of the best studied
include toll-like receptors (TLRs), nucleotide-binding oligomer-
ization domain (NOD)-like receptors (NLRs), the ATP receptor
(P2X7R), and the formyl peptide receptors (FPR-1 and FPR-2).
The downstream responses of these receptors on antigen present-
ing cells (APCs), such as dendritic cells (DCs), include increased
expression of inflammatory cytokines and the upregulation of
co-stimulation and antigen presenting molecules that play a crit-
ical role in initiating and orchestrating the resulting immune
response.
Many PRRs play a dual role in the recognition of DAMPs
and pathogen-associated molecular patterns, or “PAMPs,” derived
from microbial infection such as lipopolysaccharide (LPS) from
bacteria, single-stranded RNA from viruses, and unmethylated
CpG DNA motifs from bacteria and viral sources (4, 10–13).
Similar to DAMPs, PAMPs also contribute to the inflammatory
immune response following HSCT. For example, the loss of GI
tract integrity due to epithelial barrier damage from conditioning
regimens prior to allo-HSCT, as well as from GvHD following allo-
HSCT, allows the translocation of gut commensal bacteria into the
systemic circulation (14). In addition, the immune-compromised
HSCT recipient is at high risk for viral, bacterial, and fungal infec-
tions, all potent sources of PAMPs. A complete discussion of the
activation of the innate immune system by PAMPs is outside the
scope of this review, but has been reviewed by others (15). The rel-
ative contribution of DAMPs versus PAMPs to the inflammatory
response in the setting of Allo-HSCT is currently unclear.
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FIGURE 1 |Tissue injury in the setting of allogeneic hematopoietic
stem cell transplantation (Allo-HSCT) promotes graft-versus-host
disease (GvHD). Conditioning regimens used in HSCT, which includes total
body irradiation and chemotherapy, lead to tissue injury and the subsequent
release of danger-associated molecular patterns (DAMPs) from the
extracellular matrix (ECM) and from stressed, apoptotic and necrotic cells.
Acting on specific receptors on DAMPs activate host antigen presenting
cells (e.g., dendritic cells) through specific pattern recognition receptors
(PRRs), leading to the activation of donor-derived lymphocytes. Activated
allo-specific lymphocytes can provoke further tissue injury from GvHD. ATP,
adenosine triphosphate; ROS, reactive oxygen species; HMGB1,
high-mobility group box 1 protein; HSP, heat shock protein.
In the setting of Allo-HSCT, DAMPs released following tissue
damage and cell death caused by cytotoxic conditioning regi-
mens and GvHD have the potential to enhance immune acti-
vation and worsen GvHD. A better understanding of their role
in promoting immune activation will aid in the design of effec-
tive strategies to improve the outcome of Allo-HSCT. Here, we
briefly review the mechanisms of cell injury involved in con-
ditioning regimens for Allo-HSCT, highlight the potential cel-
lular and molecular mediators of sterile inflammation in the
setting of HSCT, and discuss potential therapeutic strategies of
regulating these pathways to control GvHD in the setting of
Allo-HSCT.
TISSUE INJURY FROM CONDITIONING REGIMENS
Multiple pathways of tissue injury occur following treatment with
ionizing radiation (16, 17). Radioactive particles transfer their
energy to tissues, resulting in the breaking of chemical bonds and
the formation on unnatural chemical bonds. Radiation also creates
free radicals and reactive oxidative species (ROS) that cause fur-
ther direct tissue damage (18, 19). Following radiation, complex
changes in cellular gene expression that vary between individuals,
can lead to indirect cell damage (20). Tissues with high rates of
proliferation, such as hematopoietic cells and enterocytes, are par-
ticularly susceptible to radiation injury as they become unable to
meet their metabolic demands and unable to repair DNA damage
prior to cell division (18).
Multiple chemotherapeutic regimens used in Allo-HSCT also
injure host cells through a variety of cytotoxic mechanisms. While
chemotherapeutic agents are dosed to be preferentially toxic to
hematopoietic stem cells, they are capable of causing injury to
most cell types (21). Efforts to decrease cell injury through the
use of non-myeloablative conditioning regimens have been asso-
ciated with decreased incidence and severity of GvHD compared
to myeloablative regimen (22–24).
Cell responses to injury and stress following chemoradiation
therapy include necrosis, apoptosis, and autophagy, all of which
are pathways that can lead to cell death and subsequent innate
immune activation (25). This response can be helpful in pro-
moting engraftment of donor cells and in strengthening the
alloimmune-dependent graft-versus-tumor (GvT) effect, or they
can elicit detrimental effects by initiating GvHD. These responses
to cell injury are described below.
RESPONSES TO CELL INJURY
NECROSIS
Necrosis is a cell death process involving cell membrane rupture
that lacks the morphological and biochemical characteristics of
autophagy or apoptosis. In the setting of HSCT, cell necrosis occurs
following bone marrow myeloablation conditioning regimens and
potentially from GvHD and infections resulting from immuno-
suppression. Although the initiating mechanisms are unclear, a
characteristic set of changes occurs within the cell. There is a rapid
loss of the cellular membrane ion potentials, cytoplasm, and cyto-
plasmic organelles swell, and there is a rise in cytosolic calcium
levels, leading to protease and phospholipase activation. Mito-
chondrial dysfunction ensues and reactive oxygen species (ROS)
are formed that further damage proteins, lipids, and DNA. Cell
membrane integrity is eventually lost and membrane rupture
occurs with release of intracellular contents into the extracellu-
lar space (26, 27). These released intracellular materials can act
as DAMPs, alerting the innate immune system that an immune
response is needed to either resolve a pathogen infection or initiate
wound healing (28).
APOPTOSIS
Apoptosis is a process of programed cell death involving mor-
phological cell changes of pyknosis, karyorrhexis, cell membrane
blebbing, and loss of cell surface adhesions (25, 29). Recipient
hematopoietic and stromal cells undergo apoptosis following con-
ditioning regimens used in HSCT, and T-cells undergo apoptosis
during GvHD (30).
The uptake of apoptotic cells by APCs can be anti-inflammatory
and even potentially tolerogenic (31, 32). Injection of apoptotic
cells at the time of HSCT has been shown to improve engraftment
and decrease allo-immunization (33, 34). In a murine model of
Allo-GvHD, the infusion of apoptotic APCs prior to Allo-HSCT
decreased GvHD severity and improved survival (35, 36). How-
ever, if not phagocytized in a timely fashion, apoptotic cells will
undergo necrosis, exposing previously hidden DAMPs. For exam-
ple, apoptotic cells from monocytes, macrophages, and multiple
cell lines cause the production of inflammatory cytokines and
chemokines (37–39), and increased apoptosis of recipient stro-
mal cells is linked to more severe cases of acute GvHD (40).
Overall, the pro- and anti-inflammatory properties of apop-
totic cells in the setting of HSCT and GvHD merits further
investigation.
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AUTOPHAGY
Cells under stress or undergoing starvation utilize autophagy to
degrade and recycle organelles and intracellular macromolecules
(41, 42). The role of autophagy in HSCT is unclear and is likely
complex due to both pro- and anti-inflammatory properties of
the autophagy process [reviewed by Leveque et al. (43)]. Treat-
ment with radiation has been shown to upregulate autophagy in
multiple cell types, particularly cells forming the gut barrier (44)
and autophagy is theorized to limit inflammation by degrading
inflammasomes (25, 45). In addition, the turnover of mitochon-
dria by autophagy (mitophagy) is critical for removing damaged
mitochondria that can be the source of multiple DAMPs (46–48).
SOURCES OF ENDOGENOUS INNATE IMMUNE ACTIVATORS
A variety of endogenous innate immune activators, or DAMPs,
released during the cell death process have been identified. The
following section will review the role of DAMPs in contributing
to APC activation in the setting of HSCT, leading to GvHD.
MITOCHONDRIA
Mitochondria are a rich endogenous source of DAMPs, and there
is increasing evidence that mitochondria play a central role in
innate immune activation leading to regulation of the adap-
tive immune response (49–52) (Figure 2). Mitochondria evolved
from an endosymbiotic relationship between eukaryotic cells
and bacteria and retain structural features common to bacteria
(53). Of particular relevance to their immune stimulating poten-
tial are their NFP-containing proteins and their circular DNA
genome featuring unmethylated CpG motifs that resemble DNA
of bacterial or viral origin. This is in contrast to mammalian
genomic DNA, where between 60 and 90% of all CpG repeats
are methylated (54).
There is growing evidence that mitochondrial DNA (mtDNA)
is released in the setting of tissue injury. For example, plasma
mtDNA is elevated in trauma patients (55), in patients with femur
fracture (56), and in patients with acute liver injury (57–59). The
release of mtDNA from injured tissue and cells may also play a
key role in the pathogenesis of autoimmune diseases such as sys-
temic lupus erythematosus (SLE) and rheumatoid arthritis (RA)
(60–63).
Specific oligodeoxynucleotides (ODNs) derived from mtDNA
have been identified that activate DCs in vitro based on their con-
tent of unmethylated CpG motifs (64). CpG ODNs are recognized
by TLR9, leading to MyD88 activation and either an interferon
(IFN) regulatory factor 3 (IRF3)- and IRF7-dependent type-1 IFN
response or an NF-κB (nuclear factor kappa-light-chain-enhancer
of activated B cells)-initiated inflammatory response, depending
on whether they localize to the endosomal or lysosomal compart-
ment, respectively (65–68). In addition, mtDNA contains a high
percentage of 8-hydroxy-2′-deoxyguanosine (8-OHG) residues
that make mtDNA resistant to DNAses and increase their inflam-
matory potential (48, 69, 70). The high content of 8-OHG is the
result of leaky oxidative machinery, the lack of efficient DNA repair
mechanisms, and the absence of protective histones.
The administration of CpG ODNs at the time of Allo-HSCT
accelerates GvHD in a host APC-TLR9-dependent manner and
a host IFN-γ-dependent manner, but independent of host IL-6,
FIGURE 2 | Mitochondria are central regulators of innate inflammatory
responses. Cells injured from conditioning regimens used in HSCT, or as
the result of GvHD, can leak mitochondria into the extracellular space
where they release mitochondrial DNA (mtDNA), N -formyl peptides (NFPs),
and adenosine triphosphate (ATP), causing host APC activation through
binding to toll-like receptor 9 (TLR9), formyl peptide receptor 1 (FPR1) and
the leukocyte purinergic receptor (P2X7R), respectively. Additionally,
mitochondria of injured cells release reactive oxygen species (ROS) and
their mtDNA may enter the endo-lysosomal compartment through the
process of mitophagy to activate TLR9. These processes coordinate the
production and maturation of inflammatory cytokines, such as interleukin
(IL)-1, IL-18, and IL-33, through the activation of NF-κB (nuclear factor
kappa-light-chain-enhancer of activated B cells) and the NLRP3 (NOD-, LRR-,
and pyrin domain-containing 3 inflammasome). ASC1, apoptosis-associated
speck-like protein containing a CARD; Casp-1, caspase-1.
IL-12, or natural killer (NK) cells (71). Interestingly, CpG admin-
istration also increased bone marrow rejection in a manner
dependent on donor APC-TLR9 activation. In an MHC-mismatch
murine model of HSCT using TLR9−/− recipient mice, the GvHD
clinical score of TLR9−/− mice was significantly lower than that
of wild-type mice, while no significant differences were observed
when weight loss was considered alone (72).
Another GvHD study examining the role of MyD88, TRIF,
TLR2/4, and TLR9 found that while deficiency in all these mol-
ecules decreased the intestinal immunopathology of GvHD, only
TLR9 deficiency improved survival (73). Deficiencies in MyD88
and TLR9 also reduced the number of apoptotic cells in the gut
in the same model of intestinal GvHD. In support of these find-
ings, the administration of an inhibitory ODN that blocks TLR9
activation was shown to decrease severity of intestinal GvHD, mea-
sured by reduction in caspase-3 staining and decreased apoptotic
cell counts (73). These results suggest a role of TLR9 activation
by unmethylated CpG containing DNA, an endogenous source of
which is mtDNA, in the inflammatory pathology of GvHD.
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Mitochondrial-encoded proteins are initiated with N -
formylmethionine residues similar to bacterial proteins (74).
NFPs-derived from mitochondrial proteins are recognized by the
formyl peptide receptors, FPR1 and FPR2, with high- and low-
affinity, respectively. FPR1 and FPR2 are seven-transmembrane
domain, G protein-coupled receptors, and their activation leads
to neutrophil calcium mobilization, p38 and Erk1/2 activation,
degranulation, oxidative burst, and chemotaxis (51). The role of
NFPs in GvHD is unknown, but intravascular gradients of NFPs
have been shown to guide neutrophils to sites of liver injury in
mice (75).
Mitochondria also produce ATP, the main source of cellular
energy, through oxidative phosphorylation. At high-extracellular
concentrations, ATP activates the cell surface purinergic receptor,
P2X7R, leading to activation of the NLRP3 inflammasome (6, 76,
77). Extracellular ATP has recently been shown to have a role in
GvHD (78). Following TBI and during the development of acute
GvHD, ATP level have been observed to be elevated in the peri-
toneal fluid of mice and humans, and GvHD survival in mice was
improved by the breakdown of ATP with apyrase, with ATP recep-
tor antagonism, and in mice genetically deficient for the P2X7
receptor (78).
Mitochondrial activation of the NLRP3 inflammasome also
occurs through the release of ROS, resulting in the produc-
tion of IL-1β and IL-18 through caspase-1 activation (79). ROS
released from neutrophils at the site of gastrointestinal tract
injury following radiation has been demonstrated. In irradi-
ated mice, neutrophils strongly upregulate inducible phagocyte
NADPH oxidase-1 (NOX1) (80). Deficiency in Cybb, the gene
coding for NOX2, impairs ROS production, and irradiated Cybb-
deficient allo-HSCT mouse recipients had protection from GVHD
and improved survival (81).
In summary, as may be predicted from their bacterial origins,
mitochondrial-derived molecules are capable of activating multi-
ple inflammatory pathways used in host defense against microbial
pathogens. There is increasing evidence that mitochondria are
potent endogenous innate immune activators that can promote
the pathogenesis of GvHD following Allo-HSCT.
EXTRACELLULAR MATRIX
Molecules from the extracellular matrix (ECM) also have been
shown to become pro-inflammatory when they are fragmented
and/or released. A number have been identified as having a
role in immune activation including heparan sulfate, fibronectin,
fibrinogen hyaluronate, biglycan, and tenascin (9, 82–88).
Hyaluronate and heparan sulfate induce DC maturation and
alloimmune activation following recognition by TLR4 (9, 83). In
a murine model examining skin manifestations of acute GvHD,
hyaluronate interactions with CD44 promotes lymphocyte adher-
ence to recipient endothelium (89). Serum heparan sulfate levels
are significantly elevated in the setting of acute GvHD in a mouse
model of Allo-HSCT (90). Increased serum heparan sulfate levels
result in increased donor T-cell activation and proliferation along
with GvHD severity. In human recipients of Allo-HSCT, similar
elevations in serum heparan sulfate are detected and correlate with
increasing GvHD grade (90).
HIGH-MOBILITY GROUP BOX PROTEIN 1
High-mobility group box protein 1 (HMGB1) is a non-histone
nuclear protein whose role is to bind DNA and regulate transcrip-
tion. HMGB1 has been implicated in causing inflammation asso-
ciated with ischemia–reperfusion injury, acute respiratory distress
syndrome, multi-organ distress syndrome, trauma, and autoim-
munity [reviewed by Bianchi et al. (91)]. Serum levels of HMGB1
are elevated in patients who developed acute GvHD following
Allo-HSCT (92). In Allo-HSCT recipients conditioned with mye-
loablation, there is an association between polymorphisms in
HMGB1 genotype and outcomes after Allo-HSCT (93). Inter-
estingly, thrombomodulin, a natural neutralizer of HMGB1, has
been demonstrated to treat refractory acute GvHD complicated
by thrombotic microangiopathy (94).
MONOSODIUM URATE CRYSTALS
In a study identifying the immune-stimulatory products of cell
damage released following treatment with ultraviolet (UV) radia-
tion, uric acid was identified as a danger signal that causes priming
of CD8+ T-cell responses. When added to DCs in vitro, uric
acid rapidly upregulates expression of costimulatory molecules
(5). Monosodium urate (MSU) is among several types of crys-
talline molecules that have been shown to initiate inflammatory
immune responses through the activation of NLRs, including
asbestos, silica, heme, and heme-like molecules (95–98). MSU
crystals are potent activators of the NALP3 inflammasome, leading
to release of IL-1β and IL-18, which act downstream to stimulate
parenchymal cells to secrete chemokines and promote neutrophil
infiltration (4, 99). In a mouse model of HSCT, uric acid levels
in the peritoneal cavity were higher post TBI and chemotherapy
pre-conditioning regimens. When uric acid depletion was induced
with early uricase administration, treated mice had improved sur-
vival and lower IL-1β levels compared to control mice (100). A
phase I study further explored the role of uric acid in GvHD by
treating patients with recombinant urate oxidase for 5 days during
their conditioning regimen for HSCT. The patients treated with
urate oxidase indeed had lower serum levels of uric acid compared
to matched controls, and, post-HSCT, these patients had a signifi-
cantly decreased incidence of acute GvHD (101). A contradictory
finding was shown in a retrospective study of 228 patients where
low levels of uric acid at the time of HSCT was associated with sig-
nificantly lower severity of GvHD (102). It was postulated that the
antioxidant capacities of uric acid are also important for the pre-
vention of GvHD and could outweigh its pro-inflammatory effects
in some cases. Further investigation is needed to understand the
competing roles of uric acid as an inflammatory mediator and an
antioxidant and its contribution to GvHD pathogenesis.
HEAT SHOCK PROTEINS
Heat shock proteins (HSPs) are molecular chaperones with a role
in the formation of tertiary and quaternary protein structures and
translocation within the cell. Numerous studies have reported
on the immune-stimulatory potential of HSPs, which can elicit
both innate and adaptive immune responses. In a human skin
explant model, a high correlation was shown between the grade of
GvHD and level of Hsp70 (103). In rats, Hsp70 expression in the
spleen and lymph nodes is increased in the setting of GvHD (104).
Frontiers in Immunology | Alloimmunity and Transplantation March 2015 | Volume 6 | Article 101 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brennan et al. Innate immune modulation of GvHD
In human patients, homozygous Hsp70 gene polymorphisms are
associated with a higher incidence and severity of GvHD (105).
THERAPEUTIC POTENTIAL
Current therapeutic strategies for the prevention and management
of acute GvHD following allogeneic HSCT rely on immuno-
suppressive medications such as corticosteroids, calcineurin
inhibitors, mTOR inhibitors (e.g., sirolimus), and antimetabo-
lites such as methotrexate and mycophenolate (106). Despite these
aggressive approaches, GvHD is the principal cause of mortal-
ity among bone marrow transplant recipients. Additionally, the
global immunosuppressive nature of these medications inter-
feres with the beneficial properties of donor lymphocytes, such
as the GvT response necessary for the prevention of tumor relapse
(107) and immune reconstitution necessary for protection against
microbial infections (108). Addressing inflammation derived from
the endogenous innate immune agonists summarized above may
provide mechanism-based treatments for GvHD.
One method to reduce endogenous inflammation derived from
the release of DAMPs from injured, necrotic, or apoptotic cells is
to reduce the severity of myeloablative conditioning before Allo-
HSCT (23, 24) (Figure 3). A balance must be obtained between
minimizing conditioning therapy and preventing rejection of the
stem cell graft by host lymphocytes. One method for improv-
ing stem cell engraftment utilizes donor NK cells to aide in the
elimination of host hematopoietic cells and augment the GvT
response (109, 110). For this purpose, donor NK cell infusion
is performed at the time of Allo-HSCT or cord blood transplanta-
tion in clinical trials for the treatment of hematologic malignan-
cies (ClinicalTrials.gov Identifier: NCT01807611, NCT01621477,
and NCT01619761). In this setting, donor NK function can be
FIGURE 3 | Inhibiting endogenous innate immune activation in the
setting of Allo-HSCT. Utilizing low-dose chemoradiation conditioning
regimens and protease inhibitors can minimize the release of DAMPs.
Specific DAMPs can be targeted for degradation, inhibited by binders, or
targeted for degradation. Antagonists can inhibit PRRs that recognize
DAMPs. A1AT, alpha-1 antitrypsin; ODN, oligodeoxynucleotide; Z-VAD-FMK,
carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone; Boc-1,
tert-butyloxycarbonyl-methionyl-leucyl-phenylalanine; PPADS,
pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonic acid; A-438079,
3-((5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methyl pyridine).
augmented using synthetic TLR9 agonists (e.g., CpG DNA), TLR3
agonists [e.g., Poly(I:C)], or IL-2 therapy.
In addition to minimizing myeloablative pre-conditioning tox-
icity, there are a number of strategies focused on targeting spe-
cific DAMPs and subsequent innate immune activation. Dying
and injured cells release ATP that activates its receptor, P2X7R,
on innate immune cells contributing to inflammatory response
to HSCT pre-conditioning therapy and GvHD (78). Wilhelm
and colleagues have shown that metabolizing extracellular ATP
with apyrase or P2X7R antagonism with pyridoxal-phosphate-
6-azophenyl-2′,4′-disulfonic acid (PPADS) is protective against
GvHD in a murine model of allo-HSCT (78). As the authors also
showed that ATP levels in the peritoneal cavity of human patients
with GvHD following HSCT are dramatically elevated, methods of
preventing the pathway of endogenous innate immune activation
seem therapeutically promising.
Endogenous DNA, particularly hypomethylated CpG-rich
mtDNA, is a TLR9-dependent innate immune activator, and meth-
ods to absorb extracellular DNA or blocking TLR9 are both poten-
tial avenues for decreasing GvHD severity. For example, using the
synthetic TLR9 receptor inhibitory oligonucleotide, ODN-2088,
Heimesaat and colleagues were able to decrease intestinal manifes-
tation of GvHD in an irradiation-independent murine Allo-HSCT
model (73). In a CpG-dependent model of acute liver failure, Lee
and colleagues were able to use DNA binding polymers in vivo to
prevent CpG related mortality in mice (111). Using these polymers
at the time of either irradiation- or chemotherapy-based condi-
tioning for Allo-HSCT, or at the onset of GvHD, has the potential
to dampen the GvHD-immune response, but has not yet been
tested.
Chemotherapy, irradiation, and GvHD result in tissue injury
that can also lead to the degradation of ECM and the release of
inflammatory glycosaminoglycans (GAGs), such as hyaluronate
and heparan sulfate. GAGs can be released directly by glycolytic
enzymes (e.g., heparanase), or by the proteolysis of extracellular
or membrane bound proteoglycans to which they are attached.
Alpha-1 antitrypsin (A1AT) is an abundant serum serine protease
inhibitor critical for the prevention of neutrophil elastase-induced
lung injury in the setting of chronic inflammation (112). The gen-
eral immunosuppressive properties of A1AT have been observed
in the prevention of acute myocardial ischemia–reperfusion injury
(113) and ischemia–reperfusion-induced lung injury (114). A1AT
has also been shown to prolong islet allograft survival in mice (115,
116). We and others have shown that administration of human
A1AT decreases GvHD in murine models of Allo-HSCT (90, 117,
118), and it has recently been shown to preserve and enhance
the NK-mediated GvT effect (119). A1AT is currently being stud-
ied in clinical trials for the treatment of steroid refractory GvHD
(ClinicalTrials.gov Identifier: NCT01700036 and NCT01523821).
Alternatively, the receptor for heparan sulfate, TLR4 (120), can be
blocked by TLR4 antagonist antibodies (121) or TLR4 inhibitors
such as Eritoran (122), TAK-242 (123), Ibudilast (124), and
glucosamine dendrimers (125).
FUTURE PERSPECTIVES
The pathogenesis of GvHD following Allo-HSCT is complex and
multifactorial, resulting in significant obstacles for progress in this
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area of research. Successful attempts to address this critical prob-
lem for Allo-HSCT patients have focused on decreasing cytotoxic
effects of chemoradiation pre-conditioning, decreasing microbial
translocation across the damaged GI tract, and, more recently, tar-
geting PRRs for both endogenous and exogenous sources of innate
immune activation.
The potential for targeting DAMPs released following cell
injury is appealing given the desire to directly target GvHD
pathophysiology and minimize attenuation of the GvT effects.
Intriguing future directions involve targeting all aspects of endoge-
nous innate immune activation, including blocking the release of
DAMPs, binding and inactivating extracellular DAMPs, blocking
or inhibiting PRRs that recognize DAMPs, and blocking intracellu-
lar signal transduction molecules downstream of PRRs (Figure 3).
As the role of intracellular DAMPs such as mitochondria and
cytoplasmic DNA in the inflammatory response is being revealed,
new insight into the pathogenesis of GvHD may be illuminated
as well.
In summary, there is increasing evidence that innate immune
activators released from damaged tissue potentiate GvHD and
that targeting these endogenous activators and their receptors is a
promising methodology for controlling GvHD while maintaining
a competent immune system.
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